Effect of troglitazone on radiation sensitivity in cervix cancer cells

Radiation Oncology Journal

Volumn 30, Issue 2, 2012, Pages 78-87

  An, Zhengzhe ^a   Liu, Xianguang ^a   Song, Hyejin ^a   Choi, Chihwan ^a   Kim, Won Dong ^a   Yu, Jae Ran ^b   Park, Woo Yoon ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

Catalase; Cell cycle; Cervix cancer; Radiation sensitivity; Reactive oxygen species; Troglitazone

Indexed keywords

EID: 84867542326     PISSN: 22341900     EISSN: 22343164     Source Type: Journal    
DOI: 10.3857/roj.2012.30.2.78     Document Type: Article

References (41)

1. Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999;4:611-7.
2. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
3. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferatoractivated receptors and cancers: complex stories. Nat Rev Cancer 2004;4:61-70.
4. Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferatoractivated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 2006;58:1-14.
5. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-52.
6. Yin F, Wakino S, Liu Z, et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 2001;286:916-22.
7. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-7.
8. Park JW, Zarnegar R, Kanauchi H, et al. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 2005;15:222-31.
9. Han S, Sidell N, Fisher PB, Roman J. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res 2004;10:1911-9.
10. Li M, Lee TW, Mok TS, Warner TD, Yim AP, Chen GG. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem 2005;96:760-74.
11. Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003;111:1381-8.
12. Kato M, Kusumi T, Tsuchida S, Tanaka M, Sasaki M, Kudo H. Induction of differentiation and peroxisome proliferatoractivated receptor gamma expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 2004;130:73-9.
13. Yu J, Qiao L, Zimmermann L, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006;43:134-43.
14. Koga H, Sakisaka S, Harada M, et al. Involvement of p21(WAF1/ Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 2001;33:1087-97.
15. Yoshizawa K, Cioca DP, Kawa S, Tanaka E, Kiyosawa K. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 2002;95:2243-51.
16. Bae MA, Rhee H, Song BJ. Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol Lett 2003;139:67-75.
17. Wang C, Pattabiraman N, Zhou JN, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol 2003;23:6159-73.
18. Huang JW, Shiau CW, Yang YT, et al. Peroxisome proliferatoractivated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol 2005;67:1342-8.
19. Tafazoli S, Wright JS, O'Brien PJ. Prooxidant and antioxidant activity of vitamin E analogues and troglitazone. Chem Res Toxicol 2005;18:1567-74.
20. Inoue I, Goto S, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001;50:3-11.
21. Heo KS, Kim DU, Ryoo S, et al. PPARgamma activation abolishes LDL-induced proliferation of human aortic smooth muscle cells via SOD-mediated down-regulation of superoxide. Biochem Biophys Res Commun 2007;359:1017-23.
22. Girnun GD, Domann FE, Moore SA, Robbins ME. Identifi cation of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol 2002;16:2793-801.
23. Okuno Y, Matsuda M, Kobayashi H, et al. Adipose expression of catalase is regulated via a novel remote PPARgammaresponsive region. Biochem Biophys Res Commun 2008;366: 698-704.
24. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazoneinduced liver failure: a case study. Am J Med 2003;114:299-306.
25. Coras R, Holsken A, Seufert S, et al. The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther 2007;6:1745-54.
26. Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 2006;13:401-13.
27. Reddy RC, Srirangam A, Reddy K, et al. Chemotherapeutic drugs induce PPAR-gamma expression and show sequencespecific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. Neoplasia 2008;10:597-603.
28. Welbourne T, Su G, Coates G, Routh R, McCarthy K, Battarbee H. Troglitazone induces a cellular acidosis by inhibiting acid extrusion in cultured rat mesangial cells. Am J Physiol Regul Integr Comp Physiol 2002;282:R1600-7.
29. Xu Y, Lu L, Greyson C, et al. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptorgamma activator in myocardial ischemia and reperfusion in pigs. Diabetes 2003;52:1187-94.
30. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006;118:773-9.
31. Turturro F, Friday E, Fowler R, Surie D, Welbourne T. Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines. Clin Cancer Res 2004;10:7022-30.
32. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006;6:53.
33. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
34. Aebi H. Catalase in vitro. Methods Enzymol 1984;105:121-6.
35. Wan XS, Zhou Z, Ware JH, Kennedy AR. Standardization of a fl uorometric assay for measuring oxidative stress in irradiated cells. Radiat Res 2005;163:232-40.
36. Yoshioka T, Fujita T, Kanai T, et al. Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 1989;32:421-8.
37. Noguchi N, Sakai H, Kato Y, et al. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 1996;123:227-34.
38. Crawford RS, Mudaliar SR, Henry RR, Chait A. Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone. Diabetes 1999;48:783-90.
39. Garg R, Kumbkarni Y, Aljada A, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 2000;36:430-5.
40. Narayanan PK, Hart T, Elcock F, et al. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment. Cytometry A 2003;52:28-35.
41. Loi CM, Young M, Randinitis E, Vassos A, Koup JR. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 1999;37:91-104.